Clinical Trial Update: Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO) [NA]

View source ↗

Summary

Phase II randomized study evaluating SBRT with Abiraterone acetate versus Abiraterone acetate alone in oligometastatic metastatic castration-resistant prostate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Lorenzo Livi | Conditions: Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone | NA | Status: UNKNOWN